We are thrilled to announce that our esteemed member, Actym Therapeutics, has successfully extended its Series A financing round with an additional $25.5 million, bringing the total amount raised in this round to a substantial $59.5 million. This milestone was announced on October 18, 2023, underlining the growing investor confidence in Actym Therapeutics’ pioneering approach towards treating solid tumors.
The additional funds will primarily fuel the advancement of Actym’s lead program, ACTM-838, into its first-in-human oncology trial, a significant step towards realizing the potential of their innovative therapies in cancer treatment. Furthermore, the funds will support the ongoing development of Actym’s proprietary STACT platform, which holds the promise of unveiling a new drug modality to the realm of oncology.
This fundraising achievement not only encapsulates the scientific and entrepreneurial spirit nurtured within Bonneville Labs but also exemplifies the incredible strides our alumni are making in the biotechnology frontier. As a part of the Bonneville Labs community, we extend our hearty congratulations to Actym Therapeutics and eagerly anticipate the remarkable innovations this funding will usher in, furthering the fight against cancer.
The extension round witnessed the participation of both existing investors including Boehringer Ingelheim Venture Fund and Illumina Ventures, and welcomed a new investor, GKCC LLC, amplifying the syndicate’s collective faith in Actym’s mission. The additional capital symbolizes a robust endorsement of Actym Therapeutics’ groundbreaking work in the field of immuno-oncology and their novel drug modality which aims to significantly impact the treatment landscape of solid tumors.